Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
CEO | Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA |
IPO Date | Jan. 26, 2018 |
Location | United States |
Headquarters | 200 Clarendon Street, Boston, MA, United States, 02116 |
Employees | 143 |
Sector | Healthcare |
Industry | Biotechnology |
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The company is also developing ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma for treating other CD70+ solid tumor and hematological malignancies indications. The company was founded in 2014 and is based in Boston, Massachusetts.
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email